DK1409544T3 - Humane DR4-antistoffer og anvendelser deraf - Google Patents

Humane DR4-antistoffer og anvendelser deraf

Info

Publication number
DK1409544T3
DK1409544T3 DK02805988T DK02805988T DK1409544T3 DK 1409544 T3 DK1409544 T3 DK 1409544T3 DK 02805988 T DK02805988 T DK 02805988T DK 02805988 T DK02805988 T DK 02805988T DK 1409544 T3 DK1409544 T3 DK 1409544T3
Authority
DK
Denmark
Prior art keywords
antibodies
human
kits
diagnosis
articles
Prior art date
Application number
DK02805988T
Other languages
English (en)
Inventor
Anan Chuntharapai
Kyung Jin Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1409544T3 publication Critical patent/DK1409544T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK02805988T 2001-07-03 2002-06-29 Humane DR4-antistoffer og anvendelser deraf DK1409544T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30322001P 2001-07-03 2001-07-03
PCT/US2002/020712 WO2003066661A2 (en) 2001-07-03 2002-06-29 Human dr4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DK1409544T3 true DK1409544T3 (da) 2009-10-26

Family

ID=27734188

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02805988T DK1409544T3 (da) 2001-07-03 2002-06-29 Humane DR4-antistoffer og anvendelser deraf

Country Status (13)

Country Link
US (2) US7252994B2 (da)
EP (2) EP1409544B1 (da)
JP (1) JP4509570B2 (da)
AT (1) ATE433996T1 (da)
AU (2) AU2002366430B2 (da)
CA (1) CA2451680C (da)
CY (1) CY1110505T1 (da)
DE (1) DE60232660D1 (da)
DK (1) DK1409544T3 (da)
ES (1) ES2328234T3 (da)
IL (1) IL159527A0 (da)
PT (1) PT1409544E (da)
WO (1) WO2003066661A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7476383B2 (en) * 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
EP1465925A4 (en) * 2001-12-20 2006-02-08 Human Genome Sciences Inc "ANTIBODIES THAT IMMUNE SPECIFICALLY TO TRAIL RECEPTORS"
ES2239886B1 (es) * 2003-11-05 2006-12-16 Universidad De Barcelona Metodo y aparato para la determinacion de la viabilidad celular.
RU2410438C2 (ru) * 2004-08-06 2011-01-27 Дженентек, Инк. Анализы и способы, использующие биомаркеры
AU2012200602B2 (en) * 2004-08-06 2012-11-08 Genentech, Inc. Assays and methods using biomarkers
DE602005027848D1 (de) 2004-08-06 2011-06-16 Genentech Inc Tests und verfahren unter verwendung von biomarkern
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
AU2006279618A1 (en) 2005-08-16 2007-02-22 Genentech, Inc. Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
US20120144504A1 (en) * 2005-10-16 2012-06-07 Yeda Research And Development Co. Ltd. Caspase-8 and skin disease
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
JP5386350B2 (ja) * 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
EP2582725A4 (en) * 2010-06-16 2014-05-07 Us Gov Health & Human Serv ANTI-DR4 AGONIST ANTIBODY
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
UA125637C2 (uk) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
US10941204B2 (en) 2015-10-30 2021-03-09 Galaxy Biotech, Llc Highly potent antibodies binding to death receptor 4
BR112018011100A2 (en) 2015-12-01 2018-12-04 Genmab B.V. antibody, composition, nucleic acid construct, expression vector, host cell, method for treating an individual having a cancer, kit of parts, and use of an antibody or composition.

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8905669D0 (en) * 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
CA2105969A1 (en) 1991-03-11 1992-09-12 Sheila Drover Murine monoclonal antibodies recognizing polymorphic determinants of hla
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1995021256A1 (fr) * 1994-02-04 1995-08-10 Bio Merieux Virus msrv1 et agent pathogene et/ou infectant msrv2 associes a la sclerose en plaques, leurs constituants nucleiques et leurs applications
KR100510234B1 (ko) 1995-06-29 2005-11-25 임뮤넥스 코포레이션 세포소멸을 유도하는 시토킨
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
DK0939804T4 (da) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
PT951551E (pt) 1996-12-23 2008-10-28 Immunex Corp Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf
EP1012274B2 (en) * 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
DE69836956T2 (de) 1997-03-17 2007-10-31 Human Genome Sciences, Inc. Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält
SI0975754T2 (sl) 1997-04-16 2016-04-29 Amgen Inc., Vezivni proteini in receptorji osteoprotegerina
EP1007562A4 (en) 1997-04-16 2000-09-27 Millennium Pharm Inc TANGO-63d AND TANGO-63e PROTEINS RELATED TO THE TUMOR NECROSIS FACTOR RECEPTOR
EP1860187B1 (en) 1997-05-15 2011-07-13 Genentech, Inc. Apo-2 receptor
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
CA2299619A1 (en) 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
AU8784498A (en) 1997-08-15 1999-03-08 Idun Pharmaceuticals, Inc. Trail receptors, nucleic acids encoding the same, and methods of use thereof
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
AU2093499A (en) 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US20040120947A1 (en) * 1998-01-26 2004-06-24 Genentech, Inc. DR4 antibodies and uses thereof
US20040180049A1 (en) * 1998-01-26 2004-09-16 Genentech, Inc. DR4 antibodies and uses thereof
PT1053256E (pt) * 1998-01-26 2011-09-28 Genentech Inc Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
ATE443723T1 (de) 1998-06-12 2009-10-15 Genentech Inc Monoklonale antikörper, kreuz-reaktive antikörper und deren produktionsverfahren
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
PT1181319E (pt) * 1999-05-28 2009-07-14 Genentech Inc Anticorpos quiméricos contra dr4 e suas utilizações
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
AU2002256895B2 (en) * 2001-05-18 2008-09-18 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
CN100594935C (zh) 2001-05-25 2010-03-24 人体基因组科学有限公司 免疫特异性结合trail受体的抗体
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
IL161686A0 (en) 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
AU2002352676A1 (en) 2001-11-14 2003-05-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors

Also Published As

Publication number Publication date
CA2451680A1 (en) 2003-08-14
DE60232660D1 (de) 2009-07-30
IL159527A0 (en) 2004-06-01
WO2003066661A2 (en) 2003-08-14
EP1409544A2 (en) 2004-04-21
WO2003066661A3 (en) 2003-11-27
CY1110505T1 (el) 2015-04-29
EP2192130A1 (en) 2010-06-02
US20040147725A1 (en) 2004-07-29
ATE433996T1 (de) 2009-07-15
US7744881B2 (en) 2010-06-29
CA2451680C (en) 2011-04-19
US7252994B2 (en) 2007-08-07
PT1409544E (pt) 2009-09-16
EP1409544A4 (en) 2005-11-09
JP4509570B2 (ja) 2010-07-21
US20080233646A1 (en) 2008-09-25
HK1065323A1 (en) 2005-02-18
AU2008260311A1 (en) 2009-01-15
AU2002366430B2 (en) 2008-09-18
AU2002366430A1 (en) 2003-09-02
JP2005517021A (ja) 2005-06-09
ES2328234T3 (es) 2009-11-11
EP1409544B1 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
CY2020003I1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις για την θεραπευτικη αγωγη της παθολογιας του crohn
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
DK0922102T3 (da) Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf
WO2004011611A3 (en) Taci antibodies and uses thereof
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
NO20061736L (no) Krystallform av epotilon B
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
DK1560812T3 (da) Aminocyclohexyletherforbindelser og anvendelser deraf
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
BR0314139A (pt) Derivados de 1,4-pirazina substituìdos
DE60335610D1 (de) Neoplasma-spezifische antikörper und deren verwendungen
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
EP1498145A4 (en) LURE FOR THE TREATMENT AND / OR PREVENTION OF ALLERGIC DISEASE ASSOCIATED WITH CYTOKINE TH2, MUTANT PROTEIN GATA3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
DK0958290T3 (da) 1,4-Dihydropyridinderivater og terapeutisk anvendelse heraf
CY1115126T1 (el) Μεθοδος και εμβολιο που περιλαμβανει συμπολυμερες 1 για θεραπεια ψυχιατρικων διαταραχων